Sangam Corporate Presentation August 2021 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-Treg and other technologies ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Aron Feingold - Head of Corporate Communications & Investor Relations Officer Sandy Macrae - President & Chief Executive Officer Prathyusha Duraibabu - Chief Financial Officer Rob Schott - Senior Vice President & Head of Development Jason Fontenot - Senior Vice President & Chief Scientific Officer Mark McClung - Executive Vice President & Chief Business Officer Conference Call Participant ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 ________________________________________________ SAN ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2021 Earnings Conference Call May 4, 2021 5:00 PM ET Company Participants Aron Feingold - Head of Corporate Communications and Investor Relations Officer Sandy Macrae - President and Chief Executive Officer Robert Schott - Senior Vice President and Head of Development Jason Fontenot - Senior Vice President and Chief Scientific Officer Mark McClung - Executive Vice President and Chief Business Officer Bettina Cockroft - Senior Vice President and Chief Medical Offic ...

Corporate Presentation May 2021 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-Treg and other technologies to develo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ (Mark One) FORM 10-Q ________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 ______ ...

Corporate Presentation February 2021 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-Treg and other technologies to d ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2020 Earnings Conference Call February 24, 2021 5:00 PM ET Company Participants Aron Feingold - Head of Corporate Communications Sandy Macrae - Chief Executive Officer Bettina Cockroft - Senior Vice President and Chief Medical Officer Jason Fontenot - Senior Vice President, Chief Scientific Officer Mark McClung - Executive Vice President and Chief Business Officer Rob Schott - Senior Vice President and Head of Development. Conference Call Participants Maurice Ray ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________ Form 10-K _______________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

| --- | --- | |-----------------------------------|-------| | | | | | | | | | | Corporate Presentation | | | | | | | | | J.P. Morgan Healthcare Conference | | | Sandy Macrae, CEO | | | January 13, 2021 | | Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies ...